May 11, 2020 / 5:18 AM / 24 days ago

BRIEF-Relief Therapeutics Filing Of IND For Phase 2/3 Clinical Trial Of Inhaled RLF-100

May 11 (Reuters) - RELIEF THERAPEUTICS Holding SA:

* ANNOUNCES FILING OF IND FOR PHASE 2/3 CLINICAL TRIAL OF INHALED RLF-100 TARGETING EARLY COVID-19 LUNG INJURY Source text - bit.ly/2AhHPBP Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below